Premium
Therapeutic Drug Monitoring in Oncology: International Association of Therapeutic Drug Monitoring and Clinical Toxicology Recommendations for 5‐Fluorouracil Therapy
Author(s) -
Beumer Jan H.,
Chu Edward,
Allegra Carmen,
Tanigawara Yusuke,
Milano Gerard,
Diasio Robert,
Kim Tae Won,
Mathijssen Ron H.,
Zhang Li,
Arnold Dirk,
Muneoka Katsuki,
Boku Narikazu,
Joerger Markus
Publication year - 2019
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1124
Subject(s) - medicine , therapeutic drug monitoring , clinical toxicology , fluorouracil , drug , oncology , clinical practice , intensive care medicine , clinical oncology , medline , pharmacology , cancer , toxicology , physical therapy , political science , law , biology
5‐Fluorouracil (5‐FU) is dosed by body surface area, a practice unable to reduce the interindividual variability in exposure. Endorsed by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT), we evaluated clinical evidence and strongly recommend TDM for the management of 5‐FU therapy in patients with colorectal or head‐and‐neck cancer receiving common 5‐FU regimens. Our systematic methodology provides a framework to evaluate published evidence in support of TDM recommendations in oncology.